Acting FDA chief Diamantas tells DeGette two Makary-era journal articles, on CAR-T trials and a rare disease pathway, were not agency guidance.
The FDA is continuing to rewind actions by former Commissioner Marty Makary, saying that two medical journal articles published over the last year did not …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Marty Makary resigned as FDA commissioner Tuesday. The next commissioner will inherit the same punishing contradictions, and a…
Endpoints News and Financial Times journalists discuss the downfall of FDA Commissioner Marty Makary, live in New York at the…
Executives from 15 rare disease-focused nonprofits met on Wednesday with acting FDA Commissioner Kyle Diamantas. In the meeting,…
Jilted biotechs coordinated a covert campaign with the Trump administration and Capitol Hill that helped push out FDA…
Brought in as an agency critic, the commissioner drew fire from drug developers and abortion foes.
U.S. Food and Drug Administration Commissioner Marty Makary, under pressure, defends himself in an interview with CNBC's David…
